首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Autocrine enhancement of leukotriene synthesis by endogenous leukotriene B4 and platelet-activating factor in human neutrophils.
【2h】

Autocrine enhancement of leukotriene synthesis by endogenous leukotriene B4 and platelet-activating factor in human neutrophils.

机译:人中性粒细胞中内源性白三烯B4和血小板活化因子的自分泌增强白三烯合成。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. Platelet-activating factor (PAF) and leukotriene B4 (LTB4), two potent lipid mediators synthesized by activated neutrophils, are known to stimulate several neutrophil functional responses. In this study, we have determined that endogenous LTB4 and PAF exert autocrine effects on LT synthesis, as well as the underlying mechanism involved. 2. Pretreatment of neutrophils with either pertussis toxin (PT), or with receptor antagonists for LTB4 and PAF, resulted in an inhibition of LT synthesis induced by calcium ionophore, A23187. This inhibition was most marked at submaximal (100-300 nM) A23187 concentrations, whilst it was least at ionophore concentrations which induce maximal LT synthesis (1-3 microM). Thus newly-synthesized PAF and LTB4 can enhance LT synthesis induced by A23187 under conditions where the LT-generating system is not fully activated. 3. In recombinant human (rh) granulocyte-macrophage colony-stimulating factor (GM-CSF)-primed neutrophils, LT synthesis in response to chemoattractants (fMet-Leu-Phe or rhC5a) was also significantly inhibited by the LTB4 receptor antagonist, and to a lesser extent by PAF receptor antagonists. 4. Further investigation revealed that LTB4 and/or PAF exert their effects on LT synthesis via an effect on arachidonic acid (AA) availability, as opposed to 5-lipoxygenase (5-LO) activation. Indeed, the receptor antagonists, as well as PT, inhibited LT synthesis and AA release to a similar extent, whereas 5-LO activation (assessed with an exogenous 5-LO substrate) was virtually unaffected under the same conditions. Accordingly, we showed that addition of exogenous LTB4 could enhance AA availability in response to chemoattractant challenge in rhGM-CSF-primed cells, without significantly affecting the 5-LO activation status.(ABSTRACT TRUNCATED AT 250 WORDS)
机译:1.已知血小板活化因子(PAF)和白三烯B4(LTB4)是由活化的中性粒细胞合成的两种有效脂质介体,可刺激多种中性粒细胞功能性反应。在这项研究中,我们已经确定内源性LTB4和PAF对LT合成及其相关机制具有自分泌作用。 2.用百日咳毒素(PT)或LTB4和PAF受体拮抗剂对中性粒细胞进行预处理,会导致钙离子载体A23187诱导的LT合成受到抑制。这种抑制作用在亚最大(100-300 nM)A23187浓度下最为明显,而在诱导最大LT合成(1-3 microM)的离子载体浓度下则最为明显。因此,新合成的PAF和LTB4可以在LT生成系统未完全激活的条件下增强A23187诱导的LT合成。 3.在重组人(rh)粒细胞-巨噬细胞集落刺激因子(GM-CSF)引发的中性粒细胞中,LTB4受体拮抗剂还显着抑制了对化学引诱剂(fMet-Leu-Phe或rhC5a)的LT合成,并且PAF受体拮抗剂的作用较小。 4.进一步的研究表明,LTB4和/或PAF通过影响花生四烯酸(AA)的可用性,而不是5-脂氧合酶(5-LO)的激活,对LT合成产生影响。实际上,受体拮抗剂以及PT在相似的程度上抑制了LT的合成和AA的释放,而在相同条件下,5-LO活化(用外源的5-LO底物评估)实际上不受影响。因此,我们表明在rhGM-CSF引发的细胞中添加外源LTB4可以增强AA的利用率,以应对化学引诱剂的攻击,而不会显着影响5-LO激活状态。(摘要截断为250个字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号